Atezolizumab (Tecentriq™) Receives FDA Approval for Bladder Cancer May 19, 2016December 14, 2022 Arthur N. Brodsky, PhD
Durvalumab Becomes Newest Immunotherapy Approved for Advanced Bladder Cancer May 5, 2017December 14, 2022 Arthur N. Brodsky, PhD